Join the RediTrex group to help and get support from people like you.
RediTrex News
Methotrexate Cuts Systolic BP in Rheumatoid Arthritis
MONDAY, Sept. 15, 2025 – For patients with rheumatoid arthritis (RA), methotrexate significantly reduces systolic blood pressure (SBP), according to a study published online July 31 in the Annals of...
Arthritis Drug, Methotrexate, Might Have Additional Heart-Healthy Benefit
TUESDAY, Sept. 9, 2025 — A common rheumatoid arthritis drug appears to also lower blood pressure, potentially reducing patients’ risk of heart disease, a new study says. Methotrexate significantly low...
Benefits of Long-Term Routine Lab Drug Toxicity Monitoring Unclear in RA
TUESDAY, Aug. 26, 2025 – For patients with rheumatoid arthritis (RA) using disease-modifying antirheumatic drugs (DMARDs), long-term routine laboratory toxicity monitoring (lt-RLTM) indicates that...
Methotrexate Noninferior to Prednisone in Pulmonary Sarcoidosis
TUESDAY, May 20, 2025 – For patients with pulmonary sarcoidosis, methotrexate is noninferior to prednisone with regard to the change from baseline to week 24 in the percentage of the predicted...
Glucarpidase Improves Outcomes in Patients With Methotrexate-Induced Kidney Toxicity
THURSDAY, Jan. 16, 2025 – For patients with methotrexate (MTX)-acute kidney injury (AKI), glucarpidase is associated with improved renal and extrarenal outcomes, according to a study published...
FDA Approves RediTrex (methotrexate) for Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Psoriasis
NASHVILLE, Tenn., Dec. 2, 2019 /PRNewswire/ – Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that it has received approval from the U.S. Food and...
Further information
Related condition support groups
Rheumatoid Arthritis, Psoriasis